Since the KDIGO CKD-MBD Guidelines were developed in 2009 two RCTs have demonstrated increased hypercalcemia without any clinically relevant benefit in PTH lowering compared to earlier studies included in the 2009 KDIGO Guidelines. This evidence concerns the gene PTH and hypercalcemia disease.